EML4-ALKfusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+non-small cell lung cancer-Reference-Cited by-同舟云学术

EML4-ALKfusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+non-small cell lung cancer

Published:2018-02-16 Issue:12 Volume:142 Page:2589-2598
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Christopoulos Petros¹²,Endris Volker³,Bozorgmehr Farastuk¹²,Elsayed Mei¹²,Kirchner Martina³,Ristau Jonas⁴,Buchhalter Ivo³,Penzel Roland³,Herth Felix J.²⁵,Heussel Claus P.²⁶,Eichhorn Martin²⁷,Muley Thomas²⁸,Meister Michael²⁸,Fischer Jürgen R.⁹,Rieken Stefan⁴,Warth Arne²³,Bischoff Helge¹,Schirmacher Peter³,Stenzinger Albrecht³,Thomas Michael¹²^ORCID

Affiliation:

1. Department of Thoracic Oncology; Thoraxklinik at Heidelberg University Hospital; Heidelberg Germany

2. Translational Lung Research Center Heidelberg (TLRC-H); Heidelberg, Germany, member of the German Center for Lung Research (DZL)

3. Institute of Pathology, Heidelberg University Hospital; Heidelberg Germany

4. Department of Radiation Oncology; Heidelberg University Hospital; Heidelberg Germany

5. Department of Pneumology; Thoraxklinik at Heidelberg University Hospital; Heidelberg Germany

6. Department of diagnostic and interventional Radiology with Nuclear Medicine; Thoraxklinik at Heidelberg University Hospital; Heidelberg Germany

7. Department of Surgery; Thoraxklinik at Heidelberg University Hospital; Heidelberg Germany

8. Translational Research Unit; Thoraxklinik at Heidelberg University Hospital; Heidelberg Germany

9. Department of Thoracic Oncology; Lungenklinik Löwenstein; Löwenstein Germany

Funder

German Center for Lung Research

German Cancer Consortium

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ijc.31275/fullpdf

Reference32 articles.

1. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

2. The anaplastic lymphoma kinase in the pathogenesis of cancer;Chiarle;Nat Rev Cancer,2008

3. Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice;Caccese;Expert Opin Pharmacother,2016

4. Targeting ALK: precision medicine takes on drug resistance;Lin;Cancer Discov,2017

5. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC;Ou;Ann Oncol,2014

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An ultra‐fast green ultra‐high‐performance liquid chromatography‐tandem mass spectrometry method for estimating the in vitro metabolic stability of zotizalkib in human liver microsomes;Journal of Separation Science;2024-08

2. Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database;Journal of Thoracic Oncology;2024-07

3. The mesenchymal morphology of cells expressing the EML4–ALK V3 oncogene is dependent on phosphorylation of Eg5 by NEK7;Journal of Biological Chemistry;2024-05

4. Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation;Journal of Oncology Pharmacy Practice;2024-04-05

5. Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK non-small cell lung cancer;2024-03-29